The multivalent vaccine BmHAT, consisting of the Brugia malayi infective larval (L3) antigens heat shock protein12.6 (HSP12.6), abundant larval transcript-2 (ALT-2) and tetraspanin large extra cellular loop (TSP-LEL), was shown to be protective in rodent models from our laboratory.
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Introduction:
Lymphatic filariasis is a chronic infection caused by the nematode parasites Wuchereria bancrofti, Brugia malayi and B. timori (1). People living in areas endemic for this disease are continuously exposed to infective third stage larvae (L3) during mosquito bites and usually test positive for antibodies against filarial antigens. Among these a small percentage of population known as endemic normal, remain truly immune to the disease (2) and carry protective antibodies against L3 in their circulation (3) . This led to the identification and successful testing of several vaccine candidates against lymphatic filariasis (4) (5) (6) (7) (8) .
Single or subunit recombinant vaccine candidates have failed to deliver a high degree of protection, unlike attenuated L3 or its fractions (4, 5) . Abundant larval transcript (ALT-2) of the lymphatic filarial parasites is the most promising vaccine candidate till date (6) (7) (8) (9) (10) (11) (12) . ALT-2 in combination with other potential antigens such as thioredoxin peroxidase-1 (6), vespid allergen homologue-1 (13) and small heat shock protein (HSP) 12.6 (14) , can confer higher level of protection in experimental animals compared to either of the antigens alone. These findings showed that combining more than one vaccine candidate into a multivalent formulation can increase protection due to synergistic action. Recently we showed that a multivalent fusion (BmHAT) of three antigens [HSP12.6, ALT-2 and tetraspanin large extra cellular loop (TSP-LEL)] synergistically conferred significant protection (15) .
Filarial infections are endemic in the developing nations such as Africa and Asia, where subject compliance to the vaccination remains a major concern especially when multiple booster doses 4 are required for effective prevention of the disease. Despite extensive vector control measures, significant natural infection is present in mosquitoes in these countries. Therefore, we hypothesized that natural infections with L3 could boost single vaccination dose. To test this hypothesis, we used trickle infections with live B. malayi L3 as booster doses following vaccination with BmHAT in gerbil models and compared the protection and immune correlates with the traditional four dose BmHAT prime-boost regimen.
Materials and methods:
Animals and parasites
Humane use of gerbils (Meriones unguiculatus) and Balb/c mice (Charles River laboratories, Wilmington, MA) in this study were approved by the IACUC committee of the University of Illinois college of Medicine at Rockford. B. malayi third stage infective parasites (L3) were obtained from NIH/NIAID Filariasis reagent repository center, University of Georgia, Athens, GA.
Preparation of vaccine DNA and protein antigens
The pVAX-BmHAT plasmid used in DNA vaccinations was constructed as described previously (15) . Recombinant BmHSP12.6 (rBmHSP), rBmALT-2 and rBmTSP were prepared as reported earlier (7, 16, 17) . rBmHAT protein was purified using Hispur TM Cobalt resin (ThermoFisher Scientific, Rockford, IL) and passed through Detoxi-Gel TM Endotoxin Removal Gel (ThermoFisher Scientific). Endotoxin levels were <1 EU/mg as determined by LAL assay (Genscript, Piscataway, NJ). 
Antibody responses against BmHAT in Balb/c mice
Balb/c mice were divided into four groups of five animals each. Group 1 received 15µg of rBmHAT protein suspended in alum (Imject alum, ThermoFisher Scientific) subcutaneously followed by 100g of pVAX-BmHAT DNA given intradermally on the same day. Group 2 received 15µg of rBmHAT protein suspended in alum. Group 3 received two priming doses of pVAX-BmHAT DNA vaccine (100µg/animal) intradermally followed by two booster doses of rBmHAT protein suspended in alum (15µg/animal) subcutaneously at two weeks interval. Group 4 served as negative controls receiving alum and pVAX given at the same schedule as group three. Blood was collected from each mouse two weeks after the last injection and sera separated. Titer of antigen-specific IgG antibodies were estimated in the sera samples using an indirect ELISA as described previously (15)
Vaccination trials in gerbils
Gerbils were divided into 5 groups consisting of 5 animals each. Group 1 (BmHAT primeboost) received two doses of 100µg of pVAX-BmHAT DNA intradermally followed by two booster doses of 15µg rBmHAT plus alum subcutaneously at two weeks interval. Group 2 (BmHAT DNA-protein L3 trickle) were immunized simultaneously on day 0 with 100g of pVAX-BmHAT DNA intradermally and 15g of rBmHAT subcutaneously as a priming dose (14, 15) . This was followed by booster infections with three doses of 10 B. malayi L3s injected subcutaneously at two weeks apart to mimic natural infections (trickle infection) (18, 19 (12, 15) . The heart, lungs, testes and lymph nodes of gerbils that received L3 trickle infections were checked for the presence of adult worms as described earlier (22).
In vitro antibody-dependent cellular cytotoxicity (ADCC) assay
To determine the larval cytotoxic function of anti-BmHAT antibodies in the sera of vaccinated gerbils, we performed an in vitro ADCC assay (15, 23) . Briefly, 10 B. malayi L3 were incubated (for 48 h at 37°C and 5% CO 2 ) with 0.5×10 5 peritoneal exudates cells from normal gerbils and 50 µl of the sera samples. B. malayi L3 incubated with cells alone; sera alone or medium alone 7 were used as controls. After incubation, larval viability was determined under a light microscope.
Parasites that were limpid and straight with no movements were counted as non-viable and if they were still limpid and straight for the next 8 hours at 37°C, they were counted as dead. Live larvae remain active even after 56 hrs. Results were expressed as percent of immobile or dead parasites to the total number of parasites in each well (12, 15) .
Antibody responses
Titer of antigen-specific anti-BmHAT, BmHSP12.6, BmALT-2 and BmTSP-LEL IgG antibodies were determined in the sera of gerbils using an indirect ELISA (15) . Briefly, wells were coated with 100ng rBmHAT, rBmHSP12.6, rBmALT-2 or rBmTSP-LEL. After blocking non-specific sites with 3% BSA, sera samples (diluted two fold serially from 1:100) were added to triplicate wells. After washing the plates, anti-mouse IgG conjugated with HRP (Thermo Fisher Scientific) was added at 1:2500 dilution (anti-gerbil antibody are not commercially available, previous studies show that anti-mouse IgG antibodies cross react with gerbil IgG). O-phenylenediamine dihydrochloride substrate was added and OD read at 492nm.
Proliferative responses
Antigen-specific proliferation of spleen cells was determined using the Kit purchased from Dojindo (Rockville, MD). Briefly, 0. 
Cytokine responses
Expression of cytokine mRNA transcripts in rBmHAT (1µg/ml) stimulated gerbil spleen cells (0.5x10 6 cells/ml in 24 well plates) were measured by qPCR (Applied Biosystems, Carsbad, CA).
Primers used are given in Table 1 . Total RNA was extracted using TRI reagent (Sigma, St.
Louis, MO) and cDNA prepared using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). PCR conditions used for amplifying the cDNA were: initial denaturation at 95°C for 10min, 35 cycles of denaturation at 95°C followed by annealing and extension at 60°C. Data were analyzed using SDS RQ study software (Applied Biosystems) and the results expressed as mean fold change.
Statistical analysis
All data are presented as Mean±SD and statistical analyses were performed using Graphpad® Prism-5. Multiple comparisons between groups were made using one-way ANOVA analyses with Tukey's test or two-way ANOVA with Bonferroni's test. Probability values (P) of <0.05
were considered statistically significant. 
Single dose vaccination followed by trickle infection induced significantly high titer of antigen-specific IgG antibodies in gerbils.
Antigen-specific IgG antibody titer (Fig.2) against rBmHAT, rBmHSP12.6, rBmALT-2 or rBmTSP-LEL were significantly higher (P<0.001-P<0.01) in the BmHAT DNA-protein L3 trickle group and in the BmHAT protein L3 trickle group compared to L3 trickle only group and negative control group. The titer of IgG antibodies against all four antigens were nearly the same in the three vaccinated groups (Fig.2) suggesting that the single day vaccination plus trickle infection induced antibody titer comparable to the traditional prime boost vaccination regimen
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(two doses of pVAXBmHAT DNA prime plus two doses of rBmHAT protein boost immunization). Antigen-specific IgG titer against rBmHAT and rBmALT-2 was significantly higher (P<0.05) in the trickle infection only group compared to the negative control group suggesting that low level multiple infection can generate anti-BmALT-2 IgG antibodies.
Antibody titer against rBmHSP12.6 and rBmTSP were not statistically significant from negative controls.
L3 Single dose of vaccination followed by trickle infection conferred significant protection against challenge infection in gerbils.
There was 53.9% reduction in adult worm establishment in gerbils vaccinated simultaneously
with BmHAT DNA and rBmHAT protein followed by L3 trickle infection. In gerbils that were vaccinated with rBmHAT protein followed by trickle infection, the reduction was 46.2% compared to the L3 trickle only group (Fig.3A) . Despite the reduction in worm establishment in vaccinated animals, the values were not statistically significant because of the high standard error in trickle infection only group.
The micropore chamber L3 challenge experiment (Fig.3B) showed that gerbils vaccinated with BmHAT prime boost gave around 70% protection compared to negative control and was significantly high compared to the other vaccinated groups (P<0.001-P<0.05). Gerbils vaccinated with pVAXBmHAT DNA plus rBmHAT protein followed by booster trickle infection (BmHAT DNA-protein L3 trickle) gave 51% protection while gerbils vaccinated with rBmHAT followed 11 by booster trickle infection resulted only in 48% protection compared to negative controls.
Interestingly, animals that received only L3 trickle infection also showed 14% protection compared to negative controls.
We also performed an ADCC assay to determine the protective nature of the anti-BmHAT antibodies in the sera of vaccinated animals. Results showed that 47% L3 death occurred when sera from BmHAT DNA-protein L3 trickle group of animals were used (Fig.3C) . Similarly, 48%
L3 death occurred when sera from BmHAT protein L3 trickle group were used. 70% L3 killing occurred when sera from BmHAT prime boost vaccinated gerbils were used. Sera samples from L3 trickle infection only group also showed some protective ability similar to that observed in our micropore chamber challenge experiment. The dead larvae were straight and non-motile with cells adhered to the surface (Fig.3E&F) , while live larvae were curled and motile with no cells adhered (Fig.3D ). These findings showed that boosting with L3 trickle infection can provide significant protection in gerbils after a single BmHAT priming.
Spleen cells from vaccinated animals proliferated in response to rBmHAT.
Spleen cells from vaccinated animals proliferated significantly (P<0.001) when incubated with rBmHAT compared to negative controls (Fig.4) suggesting the presence of antigen-specific cells in the spleens of vaccinated animals. ConA was used as a non-specific positive stimulus (Fig.4) .
Single dose vaccination plus trickle infection generated antigen-specific cells that are capable of secreting IFN-γ and IL-4.
IL-4 transcripts were predominant in rBmHAT responding spleen cells from gerbils that received
BmHAT DNA-protein plus L3 trickle infection (P<0.001) and from gerbils that received multiple BmHAT prime boost immunizations compared to controls (Fig.5) . Gerbils that received repeated low dose infections of Acanthocheilonema viteae were shown to produce significant protective antibody titers especially during L3-L4 molts against L3 antigens (18) . Our mouse studies show that significant levels of anti-BmHSP12.6, anti-BmALT-2 and anti-BmTSP-LEL IgG antibodies were elicited after single vaccination with BmHAT protein or protein plus DNA. However, these responses were substantially low compared to the four doses of traditional BmHAT DNA prime protein boost regimen suggesting that booster doses are critical. In subsequent studies, we used trickle infections as the booster dose after a single day vaccination. This resulted in significant titers of IgG antibodies comparable to the traditional BmHAT prime boost vaccination regimen. This suggested that multiple trickle infections with L3 can boost vaccine-induced antibody responses. People living in endemic areas are exposed to multiple mosquito bites consequently resulting in greater chance of multiple exposures to L3, which will be much more than the three doses that we evaluated in our experimental setting.
Roughly 1 out of 50 mosquitoes that bite in an endemic area are infected with lymphatic filariasis (24) . This can lead to continuous natural booster of the immune responses (2, 25) . Using a simple logarithmic regression model, Snow and Mitchel (20) performed a meta-analysis on published studies and showed that on an average infected mosquito can carry 6.6 L3. Based on this report we used 10 L3 as the trickle infection dose. The next question we asked is what is the minimum number of trickle infection dose required to obtain similar level of IgG titer as the prime-boost regimen? We found that just three trickle doses were sufficient to boost the vaccineinduced antigen-specific IgG titer to the prime-boost regimen level (Fig.2) . These findings suggested that trickle infection can boost vaccine-induced immune response.
Since its discovery, BmALT-2 remained as one of the most effective vaccine candidates against lymphatic filariasis conferring around 76% protection in mouse, gerbil or mastomys models (3, 6, 26) . When BmALT-2 was combined with BmHSP12.6 (14) and BmTSP-LEL as a multivalent fusion vaccine, close to 95% protection were achieved in mouse and gerbil models (15) . Gene polymorphism has been reported for TSP-2 from S. japonicum (27, 28) . However, to date there are no reports on the gene polymorphism of B. malayi or W. bancrofti TSP-2. Previously we
showed that antibodies against all three antigens in the sera of putatively immune individuals (3) can participate in the ADCC-mediated killing of B. malayi L3 in vitro (7, 12, 15) . Depletion of these antibodies from the sera abrogated the killing responses (15) . In rodent models, in vivo protective responses after vaccination restricted the migration of L3 into subcutaneous spaces where they were trapped and killed by eosinophil-rich granulomas (29, 30) . A single vaccination with rBmHAT followed by L3 trickle infection generated protective antibodies that can participate in the killing of approximately 47% L3s suggesting that significant prophylaxis can be achieved after a single vaccination followed by L3 booster infection.
A strong Th2 polarized responses occurred following vaccination with irradiated larvae (9,31), whereas, parasite fractions and recombinant products mainly elicited a mixed Th1/Th2 responses especially following a prime-boost approach (13, 32) . In this study we show that spleen cells from vaccinated gerbils that were boosted with trickle infections predominantly secreted IL-4 in 15 response to rBmHAT stimulation suggesting a polarized Th2 responses similar to that observed with irradiated larval vaccination (31, 32) . However, BmHAT DNA prime protein boost vaccination followed by trickle infection resulted in a mixed Th1/Th2 responses similar to that described previously (12) . Proliferative responses of the spleen cells to rBmHAT in vaccinated gerbils suggest the presence of memory T and B cells following vaccination and trickle booster (33).
In conclusion, we show that trickle infections with B. malayi L3 can boost vaccine-induced immunity following immunization with BmHAT and confer significant protection against challenge. Extending this finding to endemic populations who are continuously exposed to infective mosquito bites, we suggest that a single BmHAT multivalent vaccination may be effective as these individuals could be naturally boosted by the infection. 
Figure 4
Proliferative responses of gerbil spleen cells (1 x 10 5 ) stimulated with 1g/ml of rBmHAT for 72 hrs and cell proliferation determined using a colorimetric assay. Results are expressed as stimulation index. **P<0.01 and ***P<0.001 compared to negative controls.
Figure 5
Cytokine mRNA in the spleen cells of gerbils stimulated with 1 g/ml of rBmHAT for 72 hrs was quantitated using real time PCR. The results are expressed as mean fold change compared to the negative controls. *P<0.05 and ***P<0.001 compared to negative controls and + P<0.05 and +++ P<0.001 compared to L3 trickle infection only group.
